OCUL · Ocular Therapeutix, Inc
$6.96
-0.33 (-4.53%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$2.12B
Shares
219.62M
Volume · Oct 2
4.96M
Avg daily vol (3M)
2.73M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.96
Open$7.40
Day$6.94–7.43
52W close$6.88–16.11
Avg vol 30d3.0M
Short int29.9M · 13.6% float · 14.2d
Short vol53%
Last earningsAug 3, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 4 wks
filed Aug 3, 2026
call held May 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-37.1%
Trailing year
Short interest
13.6%
Latest settlement · 14.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−29%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−35%
trailing
6-month return
−21%
trailing
YTD return
−43%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
1 of 264 funds reported for Sep 30 · net +76 sh shares
Insider flow
Distributing
Net -$11.3K over 90 days · 100% sells
Short interest
Rising
13.63% of float · ▲ +6.7% MoM · 14.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
264 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+3%
Y/Y
EPS growth
−16%
Y/Y
Free cash flow
$-216.9M
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
1 of 264 funds reported for Sep 30 · net +76 sh shares
Insider flow
Distributing
Net -$11.3K over 90 days · 100% sells
Short interest
Rising
13.63% of float · ▲ +6.7% MoM · 14.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
264 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $7 · 1%
Range high $16
vs 200-day avg -28%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCUL
this stock
Ocular Therapeutix, Inc
|
$2.12B | -42.7% | +3.5% | — | 13.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCUL | -27.9% | -34.6% | -21.4% | -9.3% | -42.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -27.7% | -34.1% | -33.6% | -10.2% | -55.5% |